- Trials with a EudraCT protocol (182)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
182 result(s) found for: Pregnancy Proteins.
Displaying page 1 of 10.
EudraCT Number: 2021-003214-40 | Sponsor Protocol Number: MVX0004 | Start Date*: 2022-01-13 | |||||||||||
Sponsor Name:MinervaX Aps | |||||||||||||
Full Title: A multicentre, multinational, parallel group, observer-blind, randomised, placebo-controlled study on the Group B Streptococcus vaccine (GBS-NN/NN2), investigating the immunogenicity and safety of ... | |||||||||||||
Medical condition: Prevention of Group B Streptococcus infection in neonates. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002713-40 | Sponsor Protocol Number: MRZ60201-GL-3002 | Start Date*: 2008-11-06 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: A prospective, multicenter, randomized, rater- and subject-blind, parallel group trial to investigate the non-inferiority of NT 201, free of complexing proteins, in comparison with Clostridium botu... | |||||||||||||
Medical condition: Treatment of glabellar frown lines | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003111-31 | Sponsor Protocol Number: 2007-1-18-20-6 | Start Date*: 2008-07-21 |
Sponsor Name:Charité - Universitaetsmedizin Berlin | ||
Full Title: Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative ... | ||
Medical condition: Post-operative immunological stimulation in severe immune suppression. The study population is made up of adult, which are able to give their inform consent by their own. The patients are undergoin... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001452-55 | Sponsor Protocol Number: 204852 | Start Date*: 2018-11-26 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biolog... | |||||||||||||
Medical condition: Chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002550-32 | Sponsor Protocol Number: VIPES | Start Date*: 2012-12-21 | |||||||||||
Sponsor Name:DBV Technologies SA | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized trial to study the Viaskin® Peanut’s Efficacy and Safety for treating peanut allergy in children and adults. | |||||||||||||
Medical condition: Treatment of peanut allergy in adults and children age 6 years and older with documented hypersensitivity to peanut. The induction of clinical desensitization to peanut in patients allergic to pean... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015516-18 | Sponsor Protocol Number: 001 | Start Date*: 2010-08-06 |
Sponsor Name:Univ.-Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien | ||
Full Title: Microstructural morphological changes of the macula after intravitreal microplasmin for non-surgical treatment of vitreomacular traction syndrome | ||
Medical condition: Vitreomacular traction syndrome (VMTS) is a distinct clinical entity characterized by an incomplete separation of the posterior vitreous surface from the retina with persistent posterior hyaloid ad... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014493-18 | Sponsor Protocol Number: B1971012(6108A1-2003-EU) | Start Date*: 2010-07-20 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in... | |||||||||||||
Medical condition: Healthy volunteers (prevention of bacterial meningitis). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) ES (Completed) PL (Completed) DE (Completed) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002766-20 | Sponsor Protocol Number: CAUY922A2101 | Start Date*: 2009-02-25 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in... | ||
Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003410-18 | Sponsor Protocol Number: MRZ 60201-0605/1 | Start Date*: 2007-09-07 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: Prospective, single-arm, multicenter trial to investigate the efficacy and safety of NT 201 (botulinum neurotoxin type A free of complexing proteins) and the duration of treatment effect after one ... | |||||||||||||
Medical condition: Cervical dystonia, predominantly rotational spasmodic torticollis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003071-20 | Sponsor Protocol Number: C060401 | Start Date*: 2005-09-20 |
Sponsor Name:FIT Biotech Oyj Plc | ||
Full Title: Immunogenicity and therapeutic effects of GTU-MultiHIV B clade DNA vaccine. A randomized, controlled, phase II clinical trial in treatment-naive HIV-positive subjects | ||
Medical condition: Treatment naive HIV infected individuals | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002891-15 | Sponsor Protocol Number: 1506 | Start Date*: 2012-09-18 |
Sponsor Name:VU University Medical Center | ||
Full Title: Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma. | ||
Medical condition: Metastatic renal cell carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011022-33 | Sponsor Protocol Number: 112993 | Start Date*: 2009-05-06 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, double-blind study to evaluate the safety, reactogenicity and immunogenicity of two different formulations of GSK Biologicals’ pneumococcal protein candidate vaccine, when given as a b... | ||
Medical condition: Booster vaccination with a pneumococcal protein candidate vaccine in healthy young adults aged between 18 and 41 years old, previously primed with 2 doses of pneumococcal protein vaccine in study S... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003078-36 | Sponsor Protocol Number: 727258 | Start Date*: 2020-09-14 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: The RAS-study A reverse and anatomical prosthesis shoulder study Can we improve the prophylactic profile of antibiotic treatment in shoulder prosthesis surgery? - A clinical microdialysis study as... | |||||||||||||
Medical condition: Orthopedic infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011884-35 | Sponsor Protocol Number: SAKK 77/08 and SASL 29 | Start Date*: 2009-12-19 |
Sponsor Name:Swiss Group for Clinical Cancer Research | ||
Full Title: Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A randomized multicenter phase II trial. | ||
Medical condition: Patients with unresectable hepatocellular carcinoma. | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: HU (Ongoing) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005505-51 | Sponsor Protocol Number: DPIDM-2012-01 | Start Date*: 2013-05-01 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: Dipeptidyl peptidase-4 Inhibition in Psoriasis patients with diabetes (DIP): A Randomized Clinical Trial. | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004194-16 | Sponsor Protocol Number: IRFMN-BRC-6591 | Start Date*: 2015-01-19 | |||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
Full Title: A multicenter, single-arm, phase II study to evaluate the activity of pre-operative zoledronate in triple negative breast cancer patients, according to p53 level | |||||||||||||
Medical condition: Newly diagnosed, untreated, operable triple negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003858-31 | Sponsor Protocol Number: 300319 | Start Date*: 2023-02-16 |
Sponsor Name:Aarhus University Hospital | ||
Full Title: Evaluating the vulnerability of traditional and transposition FAMM flaps using microdialysis | ||
Medical condition: Oral cavity cancer and infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007789-51 | Sponsor Protocol Number: B1971005(6108A1-2001-WW) | Start Date*: 2009-03-23 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µ... | |||||||||||||
Medical condition: The test is a vaccine. The subjects are healthy adolescents. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012714-49 | Sponsor Protocol Number: CHUBX 2009/04 | Start Date*: 2009-11-24 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy | |||||||||||||
Medical condition: Bladder carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002322-11 | Sponsor Protocol Number: ARTemis | Start Date*: 2009-04-29 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust [...] | ||
Full Title: ARTemis : Avastin® Randomised Trial with nEo-adjuvant cheMotherapy for patients wIth early breaSt cancer | ||
Medical condition: HER2 negative invasive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.